Hodgkin Lymphoma Patient Survey: Experience with Brentuximab-vedotin (Adcetris)
If you have or had Hodgkin lymphoma and took the drug brentuximab-vedotin (Adcetris), you can help by completing our survey.
Lymphoma Canada is preparing a submission for the pan¬Canadian Oncology Drug Review (pCODR) for:
Brentuximab-vedotin (Adcetris) for Hodgkin lymphoma at high risk of relapse or progression post-ASCT.
The survey provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Thursday, August 10th and should only take 10 minutes of your time.
You may access the survey by clicking the link below:
Survey for Patients with brentuximab-vedotin (Adcetris)
